Highly active Antiretroviral therapy and viral response in HIV type 2 infection

被引:31
作者
Mullins, C
Eisen, G
Popper, S
Sarr, AD
Sankalé, JL
Berger, JJ
Wright, SB
Chang, HR
Coste, G
Cooley, TP
Rice, P
Skolnik, PR
Sullivan, M
Kanki, PJ
机构
[1] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA
[2] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA
[3] Boston Univ, Med Ctr, Dept Med, Ctr HIV AIDS Care & Res, Boston, MA USA
[4] Boston Univ, Dept Med, Hematol Oncol Sect, Boston, MA 02215 USA
[5] Boston Univ, Dept Med, Infect Dis Sect, Boston, MA 02215 USA
[6] Boston Univ, Sch Med, Boston, MA 02118 USA
[7] Boston Med Ctr, Boston, MA USA
[8] Cambridge Hosp, Dept Infect Dis, Cambridge, MA 02139 USA
[9] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA
[10] St Barnabas Hosp, Dept Infect Dis, Bronx, NY USA
关键词
D O I
10.1086/421390
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Human immunodeficiency virus type 2 (HIV-2), the second human retrovirus known to cause AIDS, is endemic to West Africa but is infrequently found outside this region. We present a case series of 10 HIV-2-infected individuals treated in the United States. Physicians applied the principles of highly active antiretroviral therapy (HAART), normally used in treating HIV type 1, with modifications considered appropriate for treating HIV-2. CD4(+) cell count, HIV-2 virus load, and clinical status were found to correlate well, providing evidence that HIV-2 virus load is useful in managing treatment of patients with HIV-2 who are receiving therapy. However, HAART regimens with predicted efficacy for treatment of HIV type 1 infection are not as efficacious for treatment of HIV-2. Controlled clinical trials of HIV-2-infected patients receiving various HAART regimens are needed to provide therapeutic guidance to the medical community.
引用
收藏
页码:1771 / 1779
页数:9
相关论文
共 37 条
[1]   Antiretroviral therapy in HIV-2-infected patients:: changes in plasma viral load, CD4+cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire [J].
Adjé-Touré, CA ;
Cheingsong, R ;
Garcìa-Lerma, JG ;
Eholié, S ;
Borget, MY ;
Bouchez, JM ;
Otten, RA ;
Maurice, C ;
Sassan-Morokro, M ;
Ekpini, RE ;
Nolan, M ;
Chorba, T ;
Heneine, W ;
Nkengasong, JN .
AIDS, 2003, 17 :S49-S54
[2]   PROSPECTIVE COMPARISON OF MOTHER-TO-CHILD TRANSMISSION OF HIV-1 AND HIV-2 IN ABIDJAN, IVORY-COAST [J].
ADJORLOLOJOHNSON, G ;
DECOCK, KM ;
EKPINI, E ;
VETTER, KM ;
SIBAILLY, T ;
BRATTEGAARD, K ;
YAVO, D ;
DOORLY, R ;
WHITAKER, JP ;
KESTENS, L ;
OU, CY ;
GEORGE, JR ;
GAYLE, HD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (06) :462-466
[3]  
*AIDS, 1990, WKLY EPIDEMIOL REC, V65, P281
[4]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[5]  
AYANIAN JZ, 1989, NEW ENGL J MED, V320, P1422, DOI 10.1056/NEJM198905253202119
[6]  
BARIN F, 1985, LANCET, V2, P1387
[7]   Synthesis and biological activity of novel 1H,3H-thiazolo[3,4-a] benzimidazoles:: non-nucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitors [J].
Chimirri, A ;
Grasso, S ;
Monforte, P ;
Rao, A ;
Zappalà, M ;
Monforte, AM ;
Pannecouque, C ;
Witvrouw, M ;
Balzarini, J ;
De Clercq, E .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1999, 10 (04) :211-217
[8]  
Clark NM, 1998, AIDS, V12, P2506
[9]   ISOLATION OF A NEW HUMAN RETROVIRUS FROM WEST-AFRICAN PATIENTS WITH AIDS [J].
CLAVEL, F ;
GUETARD, D ;
BRUNVEZINET, F ;
CHAMARET, S ;
REY, MA ;
SANTOSFERREIRA, MO ;
LAURENT, AG ;
DAUGUET, C ;
KATLAMA, C ;
ROUZIOUX, C ;
KLATZMANN, D ;
CHAMPALIMAUD, JL ;
MONTAGNIER, L .
SCIENCE, 1986, 233 (4761) :343-346
[10]   COMPARISON OF THE SENSITIVITIES OF PRIMARY ISOLATES OF HIV TYPE-2 AND HIV TYPE-1 TO ANTIVIRAL DRUGS AND DRUG-COMBINATIONS [J].
COX, SW ;
APERIA, K ;
ALBERT, J ;
WAHREN, B .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (12) :1725-1729